Spotlight Growth
No Result
View All Result
Thursday, May 19, 2022
  • Login
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

Hoth Therapeutics (NASDAQ: HOTH) Reports its HT-KIT Novel Therapeutic Able to Block and Kill Cancer Cell Growth over 72 Hours, Orphan Drug Status Granted

by admin
April 11, 2022
in Bio/Med/Pharma
0
Hoth Therapeutics NASDAQ HOTH HT KIT Cancer Cells Spotlight Growth

Hoth Therapeutics NASDAQ HOTH HT KIT Cancer Cells Spotlight Growth

Hoth Therapeutics, Inc. (NASDAQ: HOTH) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development, and clinical testing of new generation therapies to treat unmet medical needs. Shares of the biopharma company are skyrocketing 129% through early trading on Monday, April 11, 2022. Over the past three months, Hoth Therapeutics has seen average daily volume of 764,570 shares. However, volume of 106.21 million shares or dollar volume of around $145.51 million, has already exchanged hands through early trading.

Shares of Hoth Therapeutics are surging after the company provided a development update for its mRNA frame-shifting therapeutic, HT-KIT. In a sponsored scientific research agreement with North Carolina State University, the joint team used HT-KIT on mast cell leukemia cells in vitro. The results showed the KIT protein expression, signaling and function were reduced.

This showed that treatment with HT-KIT not only stopped cancer cell growth, but it also induced cell death over 72 hours. The clinical research was conducted through a humanized mast cell leukemia mouse model and an allograft mastocytosis model.

In conjunction with the clinical results, Hoth Therapeutics’ treatment was successfully granted orphan drug status with the U.S. Food and Drug Administration. API manufacturing feasibility has also been completed.

Robb Knie, Chief Executive Officer of Hoth Therapeutics: “With our HT-KIT drug, we are flipping off a key cancer signal that’s involved in multiple aggressive cancers, such as systemic mastocytosis, mast cell leukemia, gastrointestinal stromal tumors and acute myeloid leukemia. Our approach avoids pitfalls related to KIT mutations by targeting mRNA. Our next round of preclinical studies are underway and we are excited to utilize the results for our planned Pre-IND meeting with FDA later this year.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

Tags: biopharmabiopharmaceuticalsbiotechbiotechnology stockscommon stockday tradingemerging growthHOTHHOTH StockHoth Therapeuticsinvestinginvesting newsinvestmentmedicalmedical stocksmicrocap stocksNASDAQnewspharmaceuticalspublic companyRobinhoodrobinhood stockssmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstock market newsstocksstocks to watchtradingtreatment
  • Trending
  • Comments
  • Latest
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

November 22, 2021
Alfi NASDAQ ALF Ridesharing Tablet Rollout Spotlight Growth

Alfi, Inc. (NASDAQ: ALF) Climbs 51% After Entering Into Agreement with Miami-Based Fulfillment & Distribution Center For its Ridesharing Digital Tablet Rollout

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Nvidia Ethereum Video Card Crypto

Nvidia Announces New Chip Specifically For Ethereum Mining

0
Grab Holdings NASDAQ GRAB Q1 2022 Results Spotlight Growth

Grab Holdings (NASDAQ: GRAB) Saw Strong Delivery Growth During Q1 2022, Leading to Revenue Growth and Narrowing Losses

May 19, 2022
GTX Corp OTC GTXO Q1 2022 Financial Results Spotlight Growth

GTX Corp (OTC Pink: GTXO) Reports First Quarter 2022 Financial Results and Corporate Summary Update

May 19, 2022
Security Token Group STG Series A 3 Million Spotlight Growth

Security Token Group Raises $3 Million Series A Round Led by Blue Bay Ventures

May 18, 2022
How to Play Market Downturn Spotlight Growth

How to Play the Market Downturn

May 18, 2022

Recent News

Grab Holdings NASDAQ GRAB Q1 2022 Results Spotlight Growth

Grab Holdings (NASDAQ: GRAB) Saw Strong Delivery Growth During Q1 2022, Leading to Revenue Growth and Narrowing Losses

May 19, 2022
GTX Corp OTC GTXO Q1 2022 Financial Results Spotlight Growth

GTX Corp (OTC Pink: GTXO) Reports First Quarter 2022 Financial Results and Corporate Summary Update

May 19, 2022

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • OTC:LUSI
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us
Spotlight Growth

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested